Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
life sciences
national blog main
national top stories
boston
boston blog main
boston top stories
enzyme
gene editing
san francisco blog main
san francisco top stories
agios therapeutics
arch venture partners
artificial intelligence
base editing
bill martin
bio
biopharma
branden moriarty
broad institute
cas13
clinical study
crispr therapeutics
crispr-cas9
data
david liu
deals
disease
dna
drug development
duchenne
editas medicine
editor
editr
europe blog main
europe top stories
executive
feng zhang
funding
gag
What
medicine
4
×
therapeutics
4
×
gene
betting
editing
approach
approval
beam
benefit
billion
biopharma
blackthorn
cas
challenges
company
create
crispr
deal
disorders
drugs
duchenne
editas
editor
effective
fda
finding
founders
going
gotten
gv
harvard
health
historic
humans
isn't
jump
landmark
learning
little
machine
Language
unset
Current search:
biotech
×
therapeutics
×
medicine
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@techcrunch.com
4 years ago
Neurobehavioral health company Blackthorn pulls in $76 million from GV to treat mental disorders
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M